Pfizer aims to restart late-stage trial of Duchenne gene therapy following safety setback

Pfizer expects to soon reopen enrollment in a late-stage study of its experimental gene therapy for Duchenne muscular dystrophy, indicating Tuesday that a restart could be possible in the "next few months" pending regulatory feedback.